41294-56-8
Chemical Structure
Alfacalcidol
Synonym(s): 1-hydroxycholecalciferol; 1.alpha.-Hydroxyvitamin D3
- CAS No.: 41294-56-8
- Formula:C27H44O2
- Molecular Weight:400.64
IUPAC Name: (1R,3S,Z)-5-(2-((1R,3aS,7aR,E)-7a-methyl-1-((R)-6-methylheptan-2-yl)octahydro-4H-inden-4-ylidene)ethylidene)-4-methylenecyclohexane-1,3-diol
InChIKey: OFHCOWSQAMBJIW-AVJTYSNKSA-N
SMILES: C=C1[C@H](C[C@@H](C/C1=C/C=C2[C@]3([C@@](C)([C@H](CC3)[C@@H](CCCC(C)C)C)CCC/2)[H])O)O
Biological Activity: Alfacalcidol (1-hydroxycholecalciferol) is a vitamin D active metabolites, acts as a non-selective VDR activator medication, and widely be used in the management of osteoporosis[1][2][3][4].
| Cat. No. | Product Name | Purity | Description | Pricing | |||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
|
Alfacalcidol | 99.96% | Alfacalcidol (1-hydroxycholecalciferol) is a vitamin D active metabolites, acts as a non-selective VDR activator medication, and widely be used in the management of osteoporosis. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
Alfacalcidol (Standard) | ≥98% | Alfacalcidol (Standard) is the analytical standard of Alfacalcidol. This product is intended for research and analytical applications. Alfacalcidol (1-hydroxycholecalciferol) is a vitamin D active metabolites, acts as a non-selective VDR activator medication, and widely be used in the management of osteoporosis. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
Alfacalcidol-d7 | Alfacalcidol-d7 is the deuterium labeled Alfacalcidol. Alfacalcidol (1-hydroxycholecalciferol) is a vitamin D active metabolites, acts as a non-selective VDR activator medication, and widely be used in the management of osteoporosis. | |||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
Alfacalcidol-d6 | 98.0% | Alfacalcidol-d6 is the deuterium labeled Alfacalcidol. Alfacalcidol is a non-selective VDR activator. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
References
- [1]. Galeşanu C, et al. [Postmenopausal osteoporosis. Digital Rx radiogrammetry in the diagnosis and follow-up of treatment with alfacalcidol]. Rev Med Chir Soc Med Nat Iasi. 2006 Oct-Dec;110(4):833-41. [Content Brief]
- [2]. Nuijten M, et al. Cost Effectiveness of Paricalcitol versus a Non-Selective Vitamin D Receptor Activator for Secondary Hyperparathyroidism in the UK. Clin Drug Investig. 2010;30(8):545-57. [Content Brief]
- [3]. Shiraishi A, et al. The advantage of alfacalcidol over vitamin D in the treatment of osteoporosis. Calcif Tissue Int. 1999 Oct;65(4):311-6. [Content Brief]
- [4]. Nagaoka H, et al. Alfacalcidol enhances collagen quality in ovariectomized rat bones. J Orthop Res. 2014 Aug;32(8):1030-6. [Content Brief]
